Observational studyJCO precision oncology2026
Prognostic Significance of Blood-Based Multicancer Detection in Circulating Tumor DNA: Five-Year Outcomes Analysis.
Observational study in JCO precision oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02889978 (The Circulating Cell-free Genome Atlas Study), which is not on this map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Circulating Cell-free Genome Atlas Study
Who cites it
1 citing paper in PubMed.
- Evolving Landscape for Artificial Intelligence in the Diagnosis and Histopathologic Assessment of Oral and Oropharyngeal Cancer.Head and neck pathology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeA multicancer early detection (MCED) test was developed and validated in the case-control Circulating Cell-free Genome Atlas (CCGA) study (ClinicalTrials.gov identifier: NCT02889978). Previous analysis of the second (cross-validation) CCGA substudy identified prognostic value of cancer signal detection by the MCED test with 3-year follow-up. Here, we evaluated the prognostic value of a cancer signal detected (CSD) result in the third (validation) CCGA substudy (CCGA3) using an updated statistical methodology with 5-year follow-up.
methodsCCGA3 participants with confirmed cancer were followed for up to 5 years; overall survival was stratified by MCED test result (CSD or no CSD [NCSD]). Observed survival was compared with the expected survival of a reference population calculated from Surveillance, Epidemiology, and End Results data matched to clinical characteristics (age, sex, cancer type, and stage) in each signal detection group.
resultsOf 2,513 participants with stageable, invasive cancer, 792 (31.5%) died and 1,683 (67.0%) were confirmed alive at follow-up, with 38 (1.5%) lost to follow-up. CSD rates were higher in participants who died during follow-up compared with those alive (85%
conclusionCSD cancers had long-term survival similar to expectations, even in early stages, indicating that CSD early-stage cancers are unlikely to be more micrometastatic and lethal than cancers detected by conventional means. The MCED test was likely to find clinically significant cancers without contributing to overdiagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.